Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29001094 | 0.73 | MAOA (0.32) | ALDH1A1HSD17B10 | |
| SCHEMBL2722669 | 0.71 | ALDH1A1 (0.46) | ALDH1A1HSD17B10 | |
| SCHEMBL21730010 | 0.68 | DYRK1A (0.39) | ALDH1A1HSD17B10 | |
| SCHEMBL38650866 | 0.66 | AXL (0.38) | ALDH1A1HSD17B10 | |
| SCHEMBL19725731 | 0.66 | AXL (0.38) | ALDH1A1HSD17B10 | |
| SCHEMBL29877409 | 0.66 | BACE1 (0.33) | — | |
| SCHEMBL9980542 | 0.64 | EGFR (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL28874631 | 0.64 | CYP1A2 (0.39) | ALDH1A1 | |
| SCHEMBL5929534 | 0.64 | MAPT (0.40) | ALDH1A1HSD17B10 | |
| SCHEMBL11372655 | 0.64 | MAPK10 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20060264628-A1 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| US-20060241297-A1 | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | ALDH1A1 4332/4885HSD17B10 1859/4885 |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | ALDH1A1 2669/4885HSD17B10 1426/4885 |
| US-20060264628-A1 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CDK10, CSNK1A1L, CDK20 | ALDH1A1 4633/4885HSD17B10 1017/4885 |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | ALDH1A1 1568/4885HSD17B10 2991/4885 |
| US-20060241297-A1 | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | FRK, CNKSR1, TYK2 | ALDH1A1 4406/4885HSD17B10 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.